Tepotinib PFS

PFS of Tepotinib refers to the sustained progression-free survival of Tepotinib in various malignant tumors. Tepotinib is a new selective MET type 1b inhibitor that inhibits MET phosphorylation and downstream signaling and has also been shown to be effective in patients with MET exon 14 mutations with long response duration.

Prior to human clinical trials, tepotinib initially demonstrated potent inhibitory activity againstMET in cancer cell lines and anti-tumor activity in mouse xenograft models. It also uniquely inhibits methionine regardless of HGF-dependent or -independent methionine activation. In the latest data from the VISION Phase II study, 97% of patients had metastatic disease at the start of the study. The objective response rate was 46%, the median duration of response was 11.1 months, and the median progression-free survival (PFS) was 8.5 months. On independent review, all responses were partial, although investigators considered two patients to have had complete responses. In the pretreatment arm, these results were superior to capmatinib, with a response rate of 56% (vs. 41%), demonstrating the utility of tepotinib in the pretreatment-refractory setting.

The original drug Tepotinib is already on the market in China, but it is not yet eligible for medical insurance. Tepotinib Original drug currently marketed overseas is relatively expensive, and the price of each box of 225mg*30 tablets may be around RMB 80,000 (the price may fluctuate due to exchange rates). There are already generic Tepotinib drugs produced in other countries. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is relatively cheap. For example, the price of 225mg*60 tablets produced by a Laos pharmaceutical factory may be more than 8,000 yuan per box (the price may fluctuate due to exchange rates).